CN113817744A - 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 - Google Patents
一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 Download PDFInfo
- Publication number
- CN113817744A CN113817744A CN202111339161.XA CN202111339161A CN113817744A CN 113817744 A CN113817744 A CN 113817744A CN 202111339161 A CN202111339161 A CN 202111339161A CN 113817744 A CN113817744 A CN 113817744A
- Authority
- CN
- China
- Prior art keywords
- lysin
- peptide
- nile tilapia
- protein
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000276703 Oreochromis niloticus Species 0.000 title claims abstract description 69
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 29
- 101710138881 Antimicrobial peptide NK-lysin Proteins 0.000 title claims description 27
- 108010010224 NK-lysin Proteins 0.000 claims abstract description 57
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims abstract description 46
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 29
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 29
- 241001506991 Komagataella phaffii GS115 Species 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 238000001976 enzyme digestion Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims 1
- 238000009360 aquaculture Methods 0.000 abstract description 5
- 244000144974 aquaculture Species 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract description 4
- 239000003674 animal food additive Substances 0.000 abstract description 3
- 229940124350 antibacterial drug Drugs 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000235058 Komagataella pastoris Species 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000019730 animal feed additive Nutrition 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003408 sphingolipids Chemical class 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- XAGIMRPOEJSYER-CIUDSAMLSA-N Ala-Cys-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N XAGIMRPOEJSYER-CIUDSAMLSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- CLOMBHBBUKAUBP-LSJOCFKGSA-N Ala-Val-His Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N CLOMBHBBUKAUBP-LSJOCFKGSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- NLDNNZKUSLAYFW-NHCYSSNCSA-N Asn-Lys-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLDNNZKUSLAYFW-NHCYSSNCSA-N 0.000 description 1
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 1
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 1
- JRZMCSIUYGSJKP-ZKWXMUAHSA-N Cys-Val-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JRZMCSIUYGSJKP-ZKWXMUAHSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000607471 Edwardsiella tarda Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- PHIXPNQDGGILMP-YVNDNENWSA-N Ile-Glu-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N PHIXPNQDGGILMP-YVNDNENWSA-N 0.000 description 1
- NYEYYMLUABXDMC-NHCYSSNCSA-N Ile-Gly-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)N NYEYYMLUABXDMC-NHCYSSNCSA-N 0.000 description 1
- FHPZJWJWTWZKNA-LLLHUVSDSA-N Ile-Phe-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N FHPZJWJWTWZKNA-LLLHUVSDSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- NFHJQETXTSDZSI-DCAQKATOSA-N Leu-Cys-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NFHJQETXTSDZSI-DCAQKATOSA-N 0.000 description 1
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 1
- KOSWSHVQIVTVQF-ZPFDUUQYSA-N Leu-Ile-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O KOSWSHVQIVTVQF-ZPFDUUQYSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 1
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- BTSXLXFPMZXVPR-DLOVCJGASA-N Lys-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N BTSXLXFPMZXVPR-DLOVCJGASA-N 0.000 description 1
- VSJXPNCQYGOLFM-XIRDDKMYSA-N Lys-Cys-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O VSJXPNCQYGOLFM-XIRDDKMYSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
- WLXGMVVHTIUPHE-ULQDDVLXSA-N Lys-Phe-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O WLXGMVVHTIUPHE-ULQDDVLXSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- RAAVFTFEAUAVIY-DCAQKATOSA-N Met-Glu-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N RAAVFTFEAUAVIY-DCAQKATOSA-N 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- LNICFEXCAHIJOR-DCAQKATOSA-N Pro-Ser-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LNICFEXCAHIJOR-DCAQKATOSA-N 0.000 description 1
- KIDXAAQVMNLJFQ-KZVJFYERSA-N Pro-Thr-Ala Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](C)C(O)=O KIDXAAQVMNLJFQ-KZVJFYERSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194056 Streptococcus iniae Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- KULBQAVOXHQLIY-HSCHXYMDSA-N Trp-Ile-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 KULBQAVOXHQLIY-HSCHXYMDSA-N 0.000 description 1
- IELISNUVHBKYBX-XDTLVQLUSA-N Tyr-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 IELISNUVHBKYBX-XDTLVQLUSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- BWVHQINTNLVWGZ-ZKWXMUAHSA-N Val-Cys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N BWVHQINTNLVWGZ-ZKWXMUAHSA-N 0.000 description 1
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种尼罗罗非鱼抗菌肽NK‑Lysin基因及成熟肽蛋白和应用,本发明编码了尼罗罗非鱼抗菌肽NK‑Lysin基因的ORF获得尼罗罗非鱼抗菌肽NK‑Lysin成熟肽蛋白,并利用尼罗罗非鱼抗菌肽NK‑Lysin成熟肽蛋白构建能够大量表达尼罗罗非鱼抗菌肽NK‑Lysin成熟肽重组蛋白的重组毕赤酵母GS115菌株,获得的尼罗罗非鱼抗菌肽NK‑Lysin成熟肽重组蛋白纯化后能够制备抗革兰氏阳性和/或革兰氏阴性菌的水产养殖饲料添加剂或抗菌药物或日化用品添加剂。
Description
技术领域
本发明涉及生物技术制药工业中基因工程领域,特别是一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用。
背景技术
抗菌肽(Antimicrobial Peptides,AMPs)是生物体内产生的一类具有生物学活性的小分子多肽,具有广谱的抗菌性能,在生物体先天性免疫防御方面发挥重要作用。抗菌肽是一种由基因编码,富含正电荷氨基酸残基形成的阳性短肽,能够通过静电作用与阴离子靶膜相互作用,从而破坏入侵的病原微生物被膜结构完整性,起到抗菌的效果。由于这种特殊的作用机制,抗菌肽在发挥抗菌作用的同时不容易对病原微生物产生耐药性。目前,抗菌肽已经广泛应用于畜牧业的动物饲料添加剂,而在水产养殖业中能够使用的抗菌肽添加剂种类较少。因此,生产无公害抗菌肽替代抗生素应用于水产动物饲料添加剂的原料有助于疾病预防与治疗。
尼罗罗非鱼NK-Lysin蛋白也是一种抗菌肽,由细胞毒性T淋巴细胞和自然杀伤(NK)细胞分泌,储存在溶细胞颗粒中,对多种细菌、真菌、原生动物、病毒,都具有广谱的抗菌性能。NK-Lysin蛋白属于鞘脂激活蛋白样蛋白(SALIP)家族成员,由5个外显子和4个内含子组成,其编码的成熟肽蛋白序列包含一个保守的鞘脂激活蛋白B结构域和六个半胱氨酸。NK-Lysin成熟肽保守的六个半胱氨酸通过两两配对(C1-C6;C2-C5;C3-C4)构成三对分子内二硫键,由此形成α-螺旋结构在细胞膜中形成孔,使得NK-Lysin蛋白以非特异性方式渗透穿过病原微生物的脂质双层膜,进入并且积聚于细胞质与核酸结合,最终导致病原微生物死亡。
因此,将尼罗罗非鱼NK-lysin蛋白作为一种水产养殖业病害预防与治疗药物的开发和利用将产生很高的经济价值,但采用提取或合成的方法生产NK-Lysin蛋白的工艺存在工艺复杂、成本较高、且获取量少的缺点,无法满足市场需求,提高NK-lysin蛋白产量是一个急需解决的问题。
发明内容
本发明的目的是要解决现有技术中存在的不足,提供一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用。
为达到上述目的,本发明是按照以下技术方案实施的:
本发明的第一个目的是要提供一种尼罗罗非鱼抗菌肽NK-Lysin基因,所述尼罗罗非鱼抗菌肽NK-Lysin基因的ORF序列如SEQ ID NO.1所示。
本发明的第二个目的是要提供一种尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白,利用上述尼罗罗非鱼抗菌肽NK-Lysin基因的ORF序列通过PCR扩增获得,所述尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的序列如SEQ ID NO.2所示。
本发明的第三个目的是要提供一种包含上述尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的表达重组载体。
本发明的第四个目的是要提供一种包含上述尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的重组毕赤酵母GS115菌株。
本发明的第五个目的是要提供一种重组毕赤酵母GS115菌株的制备方法,将尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的表达重组载体酶切线性化后电击导入毕赤酵母GS115菌株感受态细胞,筛选高拷贝转化子重组毕赤酵母GS115菌株。
本发明的第六个目的是要提供一种制备尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的方法,将重组毕赤酵母GS115菌株经过摇瓶发酵和甲醇诱导表达及纯化,获得高纯度尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白。
本发明的第七个目的是要提供一种利用制备尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的方法制得的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白。
本发明的第八个目的是要提供尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白在制备抗革兰氏阳性和/或革兰氏阴性菌的药物中的应用。
与现有技术相比,本发明编码了尼罗罗非鱼抗菌肽NK-Lysin基因的ORF获得尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白,并利用尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白构建能够大量表达尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的重组毕赤酵母GS115菌株,获得的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白纯化后能够制备抗革兰氏阳性和/或革兰氏阴性菌的水产养殖饲料添加剂或抗菌药物或日化用品添加剂。
附图说明
图1为尼罗罗非鱼抗菌肽NK-Lysin基因ORF及其编码成熟肽序列PCR扩增电泳图。
图2为表达重组载体pPIC9K/NK-Lysin酶切电泳图。
图3为重组毕赤酵母GS115菌株表型鉴定PCR电泳图。
图4为尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白表达与纯化SDS-PAGE凝胶电泳图。
具体实施方式
为使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步的详细说明。此处所描述的具体实施例仅用于解释本发明,并不用于限定发明。
实施例1
本实施例的尼罗罗非鱼抗菌肽NK-Lysin基因是利用本实验室尼罗罗非鱼转录组测序结果,结合在线比对NCBI BLAST(https://blast.ncbi.nlm.nih.gov/Blast.cgi)分析,筛选出NK-Lysin基因(Accession number:MF678822.1)全长序列。根据NK-Lysin基因ORF序列,设计两对引物(表1),以尼罗罗非鱼组织cDNA为模板进行巢式PCR扩增。第一轮PCR利用引物OnNK-OF/OnNK-OR扩增出尼罗罗非鱼抗菌肽NK-Lysin基因ORF序列,分子量大小为432bp。第二轮PCR利用的上游引物OnNK-MF是在ORF序列的第67位碱基起24个碱基前加入EcoRⅠ酶切位点以及3个保护碱基,下游引物OnNK-MR是在ORF序列的第408位碱基起22个碱基前加入His标签、NotⅠ酶切位点以及10个保护碱基,扩增出尼罗罗非鱼抗菌肽NK-Lysin基因编码成熟肽的序列,分子量大小为411bp。PCR扩增条件为:95℃预变性5min;95℃预变性30s,55℃退火30s,72℃延伸30s,共35个循环;最后72℃完全延伸10min。PCR扩增产物的电泳图如图1所示,图1中:M泳道:2000bp Marker;泳道1:尼罗罗非鱼抗菌肽NK-Lysin基因ORF;泳道2:尼罗罗非鱼抗菌肽NK-Lysin编码成熟肽序列。
利用琼脂糖凝胶DNA回收试剂盒(TIANGEN BIOTECH;BEIJING)纯化目的基因PCR产物,连接至T4载体(Takara Bio),重组载体导入TOP10感受态细胞,阳性克隆送至生工生物工程(SHANGHAI)股份有限公司进行测序。根据测序结果,将基因序列进行NCBI BLAST(https://blast.ncbi.nlm.nih.gov/Blast.cgi)与DNAMAN软件推导翻译的蛋白序列。NK-Lysin基因ORF序列如SEQ ID NO.1所示,其编码的尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白序列如SEQ ID NO.2所示。
表1
实施例2
利用尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的可以构建重组毕赤酵母GS115菌株,其方法为:将尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的表达重组载体酶切线性化后电击导入毕赤酵母GS115菌株感受态细胞,筛选高拷贝转化子重组毕赤酵母GS115菌株,以下进行详细阐述。
首先,构建真核表达重组载体pPIC9K/NK-Lysin,具体操作如下:
利用EcoRⅠ和NotⅠ限制性内切酶(Takara Bio)对第二轮纯化后的PCR产物和pPIC9K质粒进行双酶切37℃处理4h,酶切后产物进行琼脂糖凝胶电泳并利用琼脂糖凝胶DNA回收试剂盒(TIANGEN BIOTECH;BEIJING)回收DNA片段,利用T4 DNA连接酶(TakaraBio)37℃过夜处理,重组载体导入TOP10感受态细胞,阳性克隆送至生工生物工程(SHANGHAI)股份有限公司进行测序。筛选测序正确后的菌株,摇瓶大量培养,使用无内毒素质粒提取试剂盒(TIANGEN BIOTECH;BEIJING)提取质粒备用;构建成功的重组质粒分别命名为pPIC9K/NK-Lysin。构建成功的pPIC9K/NK-Lysin重组载体酶切电泳图如图2所示,图2中:M泳道:2000bp Marker;泳道1:重组载体pPIC9K/NK-Lysin酶切结果。
然后,需要制备毕赤酵母GS115菌株感受态细胞,具体操作如下:
挑取毕赤酵母GS115单菌落接种于10mL YPD培养基(Sangon Biotech,SHANGHAI),置于30℃、250rpm振荡过夜培养。吸取活化后的菌液加入到新鲜的100mL YPD液体培养基,置于30℃、250rpm振荡培养至OD600值达到1.3~1.5。取该培养液4℃、5000rpm离心5min,弃上清,扣干离心管壁。加入50mL冰预冷无菌水振荡重悬菌体,然后4℃、5000rpm离心5min,弃上清,吸干管壁残余液体。加入20mL 1mol/L冰预冷的无菌山梨醇溶液(Sangon Biotech,SHANGHAI)重悬菌体,然后4℃、5000rpm离心5min,弃上清,吸干管壁残余液体。最后加入200μL冰预冷的无菌山梨醇溶液振荡混匀,分装成100μL/管,-80℃冰冻保存。
其次,将表达重组载体pPIC9K/NK-Lysin电击导入毕赤酵母GS115菌株获得重组毕赤酵母GS115菌株,具体操作如下:
将-80℃保存的毕赤酵母GS115菌株接种到液体YPD培养基(Sangon Biotech,SHANGHAI)中进行活化;将pPIC9K/NK-Lysin重组质粒用SalⅠ(Takara Bio)酶切线性化,胶回收目的片段;将鲑鱼精DNA(Takara Bio)沸水浴5min迅速置于冰上备用;将上述制备的液体分别加入到预冷0.2cm的电转杯(Bio-Rad)中,混匀后置于冰上10min,然后在电转仪(Bio-Rad)中进行电击(电击条件:1500V,5ms),立即取1mol/L山梨醇500μL加入到电转杯中,吸取200μL涂布在MD平板上30℃培养3-5d。设定对照组1:空载体pPIC9K电转后,同样操作涂到MD平板上;对照组2:吸取制备的毕赤酵母GS115菌株感受态细胞200μL涂布到MD平板上。
最后,筛选高拷贝转化子重组毕赤酵母GS115菌株,具体操作如下:
通过设置G418(LIFE SCIENCES)浓度梯度1、2、3、4、5mg/mL筛选重组毕赤酵母pPIC9K/NK-Lysin-GS115菌株阳性高拷贝转化子。用灭菌牙签挑取MD平板上长出的单菌落递进接种到含有不同浓度G418的YPD平板上,置于30℃培养2-3d,挑取能在5mg/mL的G418-YPD平板上长出来的单菌落扩大培养,用酵母基因组DNA快速抽提试剂盒(TIANGENBIOTECH;BEIJING)提取基因组DNA,利用pPIC9K质粒通用引物进行PCR扩增(表1),鉴定Mut+(methanol utilization plus)或Muts(methanol utilization slow)表型。重组毕赤酵母pPIC9K/NK-Lysin-GS115菌株PCR扩增电泳结果如图3所示,图3中:1-4:GS115空载菌株;5-11:Mut+型的重组毕赤酵母pPIC9K/NK-Lysin-GS115菌株。
实施例3
重组毕赤酵母GS115菌株可以高效表达尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白,具体操作如下:
选取表型为Mut+单克隆接种于25mL BMGY液体培养基中,置于30℃、250rpm振荡培养至OD600值达到2~6;4℃、5000rpm离心5min,弃上清,重悬菌体转移至1L锥形瓶,加入0.5%~1.0%甲醇,盖上两层灭菌纱布,30℃、250rpm诱导表达96h(诱导每24h添加一次甲醇),尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白将分泌至培养液中。获得尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白后,需要对其进行纯化,具体纯化方法如下:1.塞子堵紧纯化柱底部,加入1mL Ni-NAT His-Bind Resin,静置待填料自然沉降,填充柱子,形成柱体。2.取下塞子,使液体自然流出,滤完保护液,按如下顺序洗柱:5mL ddH2O洗柱2次;2mL 1×离子缓冲液洗柱3次;5mL 1×结合缓冲液洗柱1次。3.将PBS溶解的蛋白轻轻上柱,重复3次,并收集过柱液。4.用4mL不同浓度1×咪唑(20、40、60、80、100、250mM)洗柱1次,收集每次过柱液。5.加入4mL1×剥离液洗脱蛋白,收集过柱液。6.将收集的过柱液进行SDS-PAGE检测,确定蛋白纯化效果。7.通过检测得到条带单一且大小正确的过柱液加入透析袋(规格8000-14000Da)中,透析夹夹紧,放入冷冻的1×PBS溶液中进行透析。每隔3h更换透析液,共换3次。8.透析完成后,向透析袋表面加入适量PEG 2000进行浓缩,浓缩到一定体积后,收集蛋白溶液,0.22μm滤膜过滤除菌。9.用NanaDrop 2000微量分光光度计测量浓缩蛋白浓度,随后将蛋白溶液分装于1.5mL离心管,转移至-80℃冰箱待用即得尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白。尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白表达与纯化SDS-PAGE电泳结果如图4所示,图4中:泳道1:上清表达的OnNK-Lysin蛋白;泳道2:纯化后的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白;M泳道:180-10kDa蛋白Marker。
实施例4
为了验证尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的抗菌性能,检测尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白最小抑菌浓度,具体检测过程如下:选取4株革兰氏阳性菌(金黄色葡萄球菌、枯草芽孢杆菌、无乳链球菌、海豚链球菌)和12株革兰氏阴性菌(迟缓爱德华氏菌、大肠埃希氏菌、霍乱弧菌、肺炎克雷伯氏菌、伤寒沙门氏菌、嗜水气单胞菌、宋内志贺氏菌、铜绿假单胞菌、豚鼠气单胞菌、普通变形杆菌、鼠伤寒沙门氏菌、奇异变形杆菌),分别吸取新鲜活化的菌液,用LB液体培养基稀释至1×106CFU/mL,依次吸取100μL菌液加入96孔板第1~6孔,然后依次加入100μL浓度为500、250、125、62.5、32.15、15.63μg/mL的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白,使得每孔尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的终浓度依次为250、125、62.5、32.15、15.63、7.81μg/mL;阳性对照组加入等体积终浓度为200μg/mL卡那霉素溶液,阴性对照加入等体积的无菌PBS溶液;置于37℃培养24h,酶标仪测定各孔OD600吸光值。尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白抑菌效果如表2所示。
表2
由表2可知,本发明的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白对部分革兰氏阳性和革兰氏阴性菌具有显著的抑菌效果;因此,能够用于制备抗革兰氏阳性和/或革兰氏阴性菌的水产养殖饲料添加剂或抗菌药物或日化用品添加剂。
本发明的技术方案不限于上述具体实施例的限制,凡是根据本发明的技术方案做出的技术变形,均落入本发明的保护范围之内。
序列表
<110> 广东海洋大学深圳研究院 深圳义海生物科技有限公司
<120> 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 432
<212> DNA
<213> 人工序列(尼罗罗非鱼抗菌肽NK-Lysin基因)
<400> 1
atggagatgc cttcactcat ctttccgtgc cttgtggcaa cattttcagt ccgtgctgtc 60
catggacgga ccttagaggt cagcatcgat gatgaagagg acgtggacat ggaagtcttg 120
atggggcttc caggaaagtg ctgggcttgc aagtggattt taaacaaggt gaagaaactt 180
gcaggaccaa accccactgc agagagcctg aagtcaaagt tgctctctgt ctgcgatggt 240
attggactct taaaatcact gtgccgcaaa tttgtgaagg cccaccttgg agaattaatt 300
gaggaactca caacaactga tggtgtgagg accatctgtg tcaacatggg agcatgcaag 360
tcaaaggagt tggagctgct cttttatgca gagaatggag gtccacttat tgacgttaag 420
gagcttgact ga 432
<210> 2
<211> 143
<212> PRT
<213> 人工序列(尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白)
<400> 2
Met Glu Met Pro Ser Leu Ile Phe Pro Cys Leu Val Ala Thr Phe Ser
1 5 10 15
Val Arg Ala Val His Gly Arg Thr Leu Glu Val Ser Ile Asp Asp Glu
20 25 30
Glu Asp Val Asp Met Glu Val Leu Met Gly Leu Pro Gly Lys Cys Trp
35 40 45
Ala Cys Lys Trp Ile Leu Asn Lys Val Lys Lys Leu Ala Gly Pro Asn
50 55 60
Pro Thr Ala Glu Ser Leu Lys Ser Lys Leu Leu Ser Val Cys Asp Gly
65 70 75 80
Ile Gly Leu Leu Lys Ser Leu Cys Arg Lys Phe Val Lys Ala His Leu
85 90 95
Gly Glu Leu Ile Glu Glu Leu Thr Thr Thr Asp Gly Val Arg Thr Ile
100 105 110
Cys Val Asn Met Gly Ala Cys Lys Ser Lys Glu Leu Glu Leu Leu Phe
115 120 125
Tyr Ala Glu Asn Gly Gly Pro Leu Ile Asp Val Lys Glu Leu Asp
130 135 140
Claims (8)
1.一种尼罗罗非鱼抗菌肽NK-Lysin基因,其特征在于:所述尼罗罗非鱼抗菌肽NK-Lysin基因的ORF序列如SEQ ID NO.1所示。
2.一种尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白,其特征在于,利用权利要求1所述的尼罗罗非鱼抗菌肽NK-Lysin基因的ORF序列通过PCR扩增获得,所述尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的序列如SEQ ID NO.2所示。
3.一种包含权利要求2所述尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的表达重组载体。
4.一种包含权利要求2所述的尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的重组毕赤酵母GS115菌株。
5.一种如权利要求4所述的重组毕赤酵母GS115菌株的制备方法,其特征在于:将尼罗罗非鱼抗菌肽NK-Lysin成熟肽蛋白的表达重组载体酶切线性化后电击导入毕赤酵母GS115菌株感受态细胞,筛选高拷贝转化子重组毕赤酵母GS115菌株。
6.一种制备尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的方法,其特征在于,将重组毕赤酵母GS115菌株经过摇瓶发酵和甲醇诱导表达及纯化,获得高纯度尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白。
7.一种如权利要求6所述的制备尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白的方法制得的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白。
8.如权利要求7所述的尼罗罗非鱼抗菌肽NK-Lysin成熟肽重组蛋白在制备抗革兰氏阳性和/或革兰氏阴性菌的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111339161.XA CN113817744A (zh) | 2021-11-12 | 2021-11-12 | 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111339161.XA CN113817744A (zh) | 2021-11-12 | 2021-11-12 | 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113817744A true CN113817744A (zh) | 2021-12-21 |
Family
ID=78919523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111339161.XA Pending CN113817744A (zh) | 2021-11-12 | 2021-11-12 | 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113817744A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114835824A (zh) * | 2022-04-26 | 2022-08-02 | 内江师范学院 | 一种瓦氏黄颡鱼杂合抗菌肽、制备方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145822A (zh) * | 2013-02-04 | 2013-06-12 | 中国科学院海洋研究所 | 一种鱼类NK-lysin效应因子及其应用 |
CN110643612A (zh) * | 2019-08-30 | 2020-01-03 | 中国水产科学研究院南海水产研究所 | 一种卵形鲳鲹抗菌肽NK-lysin基因及应用 |
-
2021
- 2021-11-12 CN CN202111339161.XA patent/CN113817744A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103145822A (zh) * | 2013-02-04 | 2013-06-12 | 中国科学院海洋研究所 | 一种鱼类NK-lysin效应因子及其应用 |
CN110643612A (zh) * | 2019-08-30 | 2020-01-03 | 中国水产科学研究院南海水产研究所 | 一种卵形鲳鲹抗菌肽NK-lysin基因及应用 |
Non-Patent Citations (2)
Title |
---|
YU HUANG等: "NK-lysin from Oreochromis niloticus improves antimicrobial defence against bacterial pathogens" * |
吴慧等: "斑点叉尾鮰NK-lysin成熟肽在毕赤酵母中的表达" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114835824A (zh) * | 2022-04-26 | 2022-08-02 | 内江师范学院 | 一种瓦氏黄颡鱼杂合抗菌肽、制备方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110643612B (zh) | 一种卵形鲳鲹抗菌肽NK-lysin基因及应用 | |
CN102127549B (zh) | 一组鸡Cathelicidins抗菌肽及其制备方法和应用 | |
CN110551732A (zh) | 一种卵形鲳鲹抗菌肽leap-2基因及应用 | |
CN111004317B (zh) | 一种犬重组干扰素α7及其制备方法与应用 | |
CN111420037B (zh) | 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用 | |
CN108794635A (zh) | 一种牛乳铁蛋白肽-人溶菌酶融合蛋白、基因及其应用 | |
CN111304181B (zh) | 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用 | |
CN113817744A (zh) | 一种尼罗罗非鱼抗菌肽NK-Lysin基因及成熟肽蛋白和应用 | |
CN102703457A (zh) | 一种抗菌肽基因的制备及表达方法 | |
CN109134662B (zh) | 一种可视化抗菌肽融合蛋白及其制备方法和其应用 | |
CN110256570A (zh) | 一种重组融合抗菌肽及应用 | |
CN112480227A (zh) | 一种提高鲟鱼抵抗病原菌能力的蛋白及其制备方法与应用 | |
CN101525617A (zh) | 中华绒螯蟹Crustin-1基因及体外重组表达 | |
CN108948163B (zh) | 澳洲坚果植物防御素及其应用 | |
CN113845580B (zh) | 一种尼罗罗非鱼抗菌肽β-Defensin及其表达和应用 | |
CN101565703B (zh) | 中华绒螯蟹Crustin-2基因及其重组蛋白的应用 | |
CN113862277B (zh) | 一种斜带石斑鱼抗菌肽NK-Lysin成熟肽重组蛋白制备方法和应用 | |
CN113912693A (zh) | 一种公子小丑鱼抗菌肽NK-Lysin成熟肽蛋白及其表达和应用 | |
CN102864154A (zh) | 一组鸡Cathelicidins抗菌肽及其制备方法和应用 | |
CN107058432B (zh) | 一种非甲醇诱导生产抗菌肽的方法 | |
CN111304209A (zh) | 香港巨牡蛎bpi基因、编码蛋白及克隆方法和重组香港巨牡蛎bpi基因工程菌构建方法 | |
CN115057945B (zh) | 一种杂合抗菌肽NK-LPd及其基因、载体、制备方法和应用 | |
CN113943355B (zh) | 一种鲈鱼弹状病毒g2-2m重组蛋白及其应用 | |
CN103937828A (zh) | 一种猪干扰素α1与胸腺肽α1融合蛋白的制备技术 | |
CN111116738B (zh) | 大菱鲆丝氨酸蛋白酶抑制剂h1的重组蛋白及其制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |